“…In this issue, the manuscript entitled "Individualized use of 6-mercaptopurine in Chinese children with ALL: A multicenter randomized controlled trial" by Zhou et al presents a well-performed, albeit small, randomized study comparing the benefits of TPMT/NUDT15 gene-based dosing of mercaptopurine (6MP) to standard dosing without pharmacogenomics. The goal of the study is to assess the impact of a genetic-guided dosing approach, 6 considering well-established knowledge about the influence of TPMT 7 and NUDT15 variants 8 on mercaptopurine clinical safety and dosage tolerance. TPMT and NUDT15 are both involved in the disposition of 6-mercaptopurine and its metabolites.…”